Yongchao Su
Merck & Co., Inc.
Dr. Su is a Principal Scientist at Analytical Research & Development, Merck & Co, Inc. and Supervisor of Materials and Biophysical Characterization NMR. He has extensive analytical experiences on small molecule, peptides, monoclonal antibodies and vaccines, and is currently an analytical lead on high concentration subcutaneous biological drug products. He teaches as an Adjunct Associate Professor in Colleague of Pharmacy at the University of Texas at Austin and Purdue University. He is a member in Physical Analysis Expert Committee in United States Pharmacopeia (USP), a Board member of Eastern Analytical Symposium (EAS), and Co-vice Chair of Gordon Research Conference (GRC) on molecular structure elucidation. He currently serves in the Editorial Advisory Board for Molecular Pharmaceuticals, Pharmaceutical Research, Journal of Pharmaceutical Sciences, and Magnetic Resonance in Chemistry, and as an Editor of Magnetic Resonance Letter and Amino Acids. Dr. Su has contributed over 100 publications in peer-reviewed journals (H-index = 33) on pharmaceutical, biophysical and analytical topics, and several patents on drug developments of Islatravir™ and Keytruda™.